Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?

被引:36
|
作者
Barnard, Katharine D. [1 ]
Pinsker, Jordan E. [2 ]
Oliver, Nick [3 ]
Astle, Annabel [1 ]
Dassau, Eyal [2 ,4 ]
Kerr, David [2 ]
机构
[1] Univ Southampton, Human Dev & Hlth, Fac Med, Southampton SO16 6YD, Hants, England
[2] William Sansum Diabet Ctr, Santa Barbara, CA USA
[3] Univ London Imperial Coll Sci Technol & Med, London, England
[4] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA
基金
美国国家卫生研究院;
关键词
LOOP INSULIN DELIVERY; RANDOMIZED CROSSOVER; PARTICIPANTS; ADULTS;
D O I
10.1089/dia.2014.0316
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The primary focus of artificial pancreas (AP) research has been on technical achievements, such as time in range for glucose levels or prevention of hypoglycemia. Few studies have attempted to ascertain the expectations of users of AP technology. Subjects and Methods: Persons with type 1 diabetes and parents of children with type 1 diabetes were invited to take part in an online survey concerning future use and expectations of AP technology. The survey was advertised via Twitter, Facebook, and DiabetesMine, plus advocacy groups and charities including INPUT, Diabetes UK, and the Diabetes Research and Wellness Foundation. Quantitative responses were categorized on a 5-point Likert scale. Free text responses were analyzed using content analysis. Results: Two hundred sixty-six surveys were completed over a 1-month period. Two hundred forty participants indicated they were highly likely to use a fully automated 24-h AP. Approximately half of the respondents indicated they would be likely to use a device that only functioned overnight. Size, visibility, and lack of effectiveness were the top reasons for not wanting an AP. Despite perceived potential downsides, participants expressed a strong need for a device that will help minimize the burden of disease, help facilitate improved psychosocial functioning, and improve quality of life. Conclusions: The views of people who would use an AP are crucial in the development of such devices to ensure they are fit for use alongside biomedical and engineering excellence. Without this, it is unlikely that an AP will be sufficiently successful to meet the needs of users and to achieve their ultimate goals.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [41] Perceptions and expectations of adults with type 1 diabetes for the use of artificial pancreas systems with and without glucagon addition: Results of an online survey
    Taleb, Nadine
    Quintal, Ariane
    Rakheja, Rohan
    Messier, Virginie
    Legault, Laurent
    Racine, Eric
    Rabasa-Lhoret, Remi
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (02) : 658 - 665
  • [42] Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes
    Braune, Katarina
    O'Donnell, Shane
    Cleal, Bryan
    Lewis, Dana
    Tappe, Adrian
    Willaing, Ingrid
    Hauck, Bastian
    Raile, Klemens
    JMIR MHEALTH AND UHEALTH, 2019, 7 (07):
  • [43] Fully Integrated Artificial Pancreas in Type 1 Diabetes: Modular Closed-Loop Glucose Control Maintains Near Normoglycemia
    Breton, Marc
    Farret, Anne
    Bruttomesso, Daniela
    Anderson, Stacey
    Magni, Lalo
    Patek, Stephen
    Man, Chiara Dalla
    Place, Jerome
    Demartini, Susan
    Del Favero, Simone
    Toffanin, Chiara
    Hughes-Karvetski, Colleen
    Dassau, Eyal
    Zisser, Howard
    Doyle, Francis J., III
    De Nicolao, Giuseppe
    Avogaro, Angelo
    Cobelli, Claudio
    Renard, Eric
    Kovatchev, Boris
    DIABETES, 2012, 61 (09) : 2230 - 2237
  • [44] Living with type 1 diabetes: what really matters?
    Wilmot, Emma G.
    PRACTICAL DIABETES, 2021, 38 (04) : 45 - 50
  • [45] The Efficacy of Basal Rate and Carbohydrate Ratio Learning Algorithm for Closed-Loop Insulin Delivery (Artificial Pancreas) in Youth with Type 1 Diabetes in a Diabetes Camp
    Palisaitis, Emilie
    El Fathi, Anas
    Von Oettingen, Julia E.
    Krishnamoorthy, Preetha
    Kearney, Robert
    Jacobs, Peter
    Rutkowski, Joanna
    Legault, Laurent
    Haidar, Ahmad
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (03) : 185 - 194
  • [46] Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes
    Schoelwer, Melissa J.
    Robic, Jessica L.
    Gautier, Thibault
    Fabris, Chiara
    Carr, Kelly
    Clancy-Oliveri, Mary
    Brown, Sue A.
    Anderson, Stacey M.
    DeBoer, Mark D.
    Chernavvsky, Daniel R.
    Breton, Marc D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (08) : 594 - 601
  • [47] Home Use of an Artificial Beta Cell in Type 1 Diabetes
    Thabit, H.
    Tauschmann, M.
    Allen, J. M.
    Leelarathna, L.
    Hartnell, S.
    Wilinska, M. E.
    Acerini, C. L.
    Dellweg, S.
    Benesch, C.
    Heinemann, L.
    Mader, J. K.
    Holzer, M.
    Kojzar, H.
    Exall, J.
    Yong, J.
    Pichierri, J.
    Barnard, K. D.
    Kollman, C.
    Cheng, P.
    Hindmarsh, P. C.
    Campbell, F. M.
    Arnolds, S.
    Pieber, T. R.
    Evans, M. L.
    Dunger, D. B.
    Hovorka, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) : 2129 - 2140
  • [48] Artificial Intelligence in Decision Support Systems for Type 1 Diabetes
    Tyler, Nichole S.
    Jacobs, Peter G.
    SENSORS, 2020, 20 (11)
  • [49] Blood Glucose Regulation Models in Artificial Pancreas for Type-1 Diabetic Patients
    Chandrasekhar, Abishek
    Padhi, Radhakant
    JOURNAL OF THE INDIAN INSTITUTE OF SCIENCE, 2023, 103 (01) : 353 - 364
  • [50] What's new in the management of type 1 diabetes in pregnancy?
    Lee, Tara T. M.
    Murphy, Helen R.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2022, 83 (12)